The effect of dose on the antimalarial efficacy of artemether-lumefantrine: A systematic review and pooled analysis of individual patient data

The Lancet Infectious Diseases

Volumn 15, Issue 6, 2015, Pages 692-702

  Anstey, N M ^a   Price, R N ^a,ab,cb   Davis, T M E ^b   Karunajeewa, H A ^c,d   Mueller, I ^c,ay   D'Alessandro, U ^e,bu   Massougbodji, A ^f   Nikiema, F ^g   Ouedraogo J B ^g,h   Tinto, H ^g,h   Zongo, I ^g   Same Ekobo, A ⁱ   Kone M ^j   Menan, H ^j   Yavo, W ^j,l   Toure A O ^k   Kofoed, P E ^m,x   Alemayehu, B H ⁿ   Jima, D ^o   Baudin, E ^p   Espie E ^p   Nabasumba, C ^p,by   Pinoges, L ^p   Schramm, B ^p   Cot, M ^q,r   Deloron, P ^q,r   Faucher, J F ^q,r,s   Guthmann, J P ^t   Lell, B ^u,v   Borrmann, S ^v,z   Adjei, G O ^w   Ursing, J ^x,be   Tjitra, E ^y   Marsh, K ^z,cb   Peshu, J ^z   Juma, E ^z   Ogutu, B R ^z   Omar, S A ^aa   Sawa, P ^aa   Talisuna, A O ^ab,ac   Khanthavong, M ^ad   Mayxay, M ^ae,af   Newton, P N ^ab,ae,cb   Piola, P ^ag   Djimde A A ^ah   Doumbo, O K ^ah   Fofana, B ^ah   Sagara, I ^ah   Bassat, Q ^ai,ay   Gonzalez R ^ai,ay   Menendez C ^ai,ay   Smithuis, F ^aj,ak   Bousema, T ^al,bz   Kager, P A ^am   Mens, P F ^am,an   Schallig, H D F H ^an   Van den Broek, I ^ao,az   Van Vugt, M ^ap   Ibrahim, M L ^aq   Falade, C O ^ar   Meremikwu, M ^as,at   Gil, J P ^au,be,cg   Karema, C ^av   Ba, M S ^aw   Faye, B ^aw   Faye, O ^aw   Gaye, O ^aw   Ndiaye, J L ^aw   Pene, M ^aw   Sow, D ^aw   Sylla, K ^aw   Tine, R C K ^aw   Penali, L K ^ab   Barnes, K I ^ab,ax   Workman, L J ^ab,ax   Lima, A ^az   Adam, I ^ba   Gadalla, N B ^bb,bz,cf   Malik, E F M ^bc   Bjorkman A ^bd   Martensson A ^be   Ngasala, B E ^be,bp   Rombo, L ^bd,bf,bg   Aliu, P ^bh   Duparc, S ^bi   Filler, S ^bj   Genton, B ^bk,bl   Hodel, E M ^bk,cc   Olliaro, P ^bm,cb   Abdulla, S ^bn   Kamugisha, E ^bo   Premji, Z ^bp   Shekalaghe, S A ^bn,bq   Ashley, E A ^br,bs   Carrara, V I ^br,bt   McGready, R ^br,cb   Nosten, F ^br,cb   Faiz, A M ^bs   Lee, S J ^bs,cb   White, N J ^bs,cb   Dondorp, A M ^bt,cb   Smith, J J ^ab   Tarning, J ^ab,bs,cb   Achan, J ^bv   Bukirwa, H ^bv   Yeka, A ^bv   Arinaitwe, E ^bw   Staedke, S G ^bw,bz   Kamya, M R ^bx   Kironde, F ^bx   Drakeley, C J ^bz   Oguike, M ^bz   Sutherland, C J ^bz   Checchi, F ^ca   Dahal, P ^ab,cb   Flegg, J A ^ab,cb   Guerin, P J ^ab,cb   Moreira, C ^ab,cb   Nsanzabana, C ^ab,cb   Sibley, C H ^ab,ch   Stepniewska, K ^ab   Gething, P W ^ac   Hay, S I ^ac   Greenwood, B ^bz   Ward, S A ^cc   Winstanley, P A ^cd   Dorsey, G ^ce   Greenhouse, B ^ce   Rosenthal, P J ^ce   Grivoyannis, A ^ch   Hamed, K ^bh   Hwang, J ^ci,cj   Kachur, P S ^ci   Nambozi, M ^ck   more..

^a MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d WESTERN HEALTH   (Australia)

^e INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^f UNIVERSITY OF ABOMEY CALAVI   (Benin)

^g Institut de Recherche en Sciences de la Santé   (Burkina Faso)

^h CENTRE MURAZ   (Burkina Faso)

ⁱ Universite de Yaounde I Faculte de Medecine   (Cameroon)

^j UNIVERSITÉ FÉLIX HOUPHOUËT BOIGNY   (Côte d’Ivoire)

^k INSTITUT PASTEUR DE CÔTE D'IVOIRE   (Côte d’Ivoire)

^l National Institute of Public Health   (Côte d’Ivoire)

^m KOLDING HOSPITAL   (Denmark)

ⁿ International Center for AIDS Care and Treatment Programs   (Ethiopia)

^o FEDERAL MINISTRY OF HEALTH   (Ethiopia)

^p EPICENTRE   (France)

^q INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^r UNIVERSITÉ PARIS DESCARTES   (France)

^s UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^t INSTITUT DE VEILLE SANITAIRE   (France)

^u German Center for Infection Research CERMEL   (Gabon)

^v UNIVERSITY OF TÜBINGEN   (Germany)

^w UNIVERSITY OF GHANA   (Ghana)

^x Projecto de Saude de Bandim   (Guinea-Bissau)

^y NATIONAL INSTITUTE OF HEALTH RESEARCH AND DEVELOPMENT   (Indonesia)

^z KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^aa INTERNATIONAL CENTRE OF INSECT PHYSIOLOGY AND ECOLOGY ICIPE   (Kenya)

^ab WorldWide Antimalarial Resistance Network   (United Kingdom)

^ac UNIVERSITY OF OXFORD   (United Kingdom)

^ad Centre of Malariology   (Laos)

^ae MAHOSOT HOSPITAL   (Laos)

^af NATIONAL UNIVERSITY OF LAOS   (Laos)

^ag INSTITUT PASTEUR DE MADAGASCAR   (Madagascar)

^ah UNIVERSITY OF BAMAKO   (Mali)

^ai Manhiça Health Research Center   (Mozambique)

^aj Myanmar   (Myanmar)

^ak Medical Action Myanmar   (Myanmar)

^al RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^am ACADEMIC MEDICAL CENTER   (Netherlands)

^an ROYAL TROPICAL INSTITUTE   (Netherlands)

^ao NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^ap UNIVERSITY OF AMSTERDAM   (Netherlands)

^aq Centre de Recherche Médicale et Sanitaire   (Niger)

^ar UNIVERSITY OF IBADAN   (Nigeria)

^as UNIVERSITY OF CALABAR   (Nigeria)

^at Vector Group   (United Kingdom)

^au UNIVERSITY OF LISBON   (Portugal)

^av Ministry of Health   (Rwanda)

^aw UNIVERSITÉ CHEIKH ANTA DIOP   (Senegal)

^ax UNIVERSITY OF CAPE TOWN   (South Africa)

^ay Centre de Recerca en Salut Internacional de Barcelona   (Spain)

^az MÉDECINS SANS FRONTIÈRES   (Switzerland)

^ba UNIVERSITY OF KHARTOUM   (Sudan)

^bb TROPICAL MEDICINE RESEARCH INSTITUTE   (Sudan)

^bc FEDERAL MINISTRY OF HEALTH   (Sudan)

^bd KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^be KAROLINSKA INSTITUTE   (Sweden)

^bf Department of Medicine Solna ^*  (Sweden)

^bg Centre for Clinical Research   (Sweden)

^bh NOVARTIS PHARMA AG   (Switzerland)

^bi Medicines for Malaria Venture   (Switzerland)

^bj TUBERCULOSIS AND MALARIA   (Switzerland)

^bk SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^bl LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^bm UNICEF   (United States)

^bn IFAKARA HEALTH INSTITUTE   (Tanzania)

^bo CATHOLIC UNIVERSITY OF HEALTH AND ALLIED SCIENCES   (Tanzania)

^bp MUHIMBILI UNIVERSITY OF HEALTH AND ALLIED SCIENCES   (Tanzania)

^bq KILIMANJARO CHRISTIAN MEDICAL CENTRE   (Tanzania)

^br SHOKLO MALARIA RESEARCH UNIT   (Thailand)

^bs MAHIDOL UNIVERSITY   (Thailand)

^bt MAHIDOL OXFORD TROPICAL MEDICINE RESEARCH UNIT   (Thailand)

^bu MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

^bv Uganda Malaria Surveillance Project   (Uganda)

^bw INFECTIOUS DISEASES RESEARCH COLLABORATION   (Uganda)

^bx MAKERERE UNIVERSITY   (Uganda)

^by MBARARA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Uganda)

^bz LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^ca SAVE THE CHILDREN   (United Kingdom)

^cb UNIVERSITY OF OXFORD   (United Kingdom)

^cc LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^cd UNIVERSITY OF WARWICK   (United Kingdom)

^ce UNIVERSITY OF CALIFORNIA   (United States)

^cf NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^cg BINGHAMTON UNIVERSITY   (United States)

^ch UNIVERSITY OF WASHINGTON   (United States)

^ci CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^cj UNIVERSITY OF CALIFORNIA   (United States)

^ck TROPICAL DISEASES RESEARCH CENTRE   (Zambia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMETHER; ARTEMETHER PLUS BENFLUMETOL; BENFLUMETOL; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; DRUG COMBINATION; ETHANOLAMINE DERIVATIVE; FLUORENE DERIVATIVE; PROTOZOAL DNA;

AFRICA; ARTICLE; ASIA; CLINICAL TRIAL (TOPIC); DOSE RESPONSE; DRUG EFFICACY; ENDEMIC DISEASE; GAMETOCYTE; HUMAN; LOW RISK POPULATION; MALARIA; PARASITE CLEARANCE; PARASITEMIA; PATIENT CODING; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECURRENT DISEASE; RISK FACTOR; SYSTEMATIC REVIEW; TREATMENT FAILURE; ADOLESCENT; ADULT; AGED; CHILD; DRUG COMBINATION; FEMALE; GENETICS; INFANT; ISOLATION AND PURIFICATION; MALARIA, FALCIPARUM; MALE; MIDDLE AGED; PRESCHOOL CHILD; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AFRICA; AGED; AGED, 80 AND OVER; ANTIMALARIALS; ARTEMISININS; ASIA; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; DNA, PROTOZOAN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; ETHANOLAMINES; FEMALE; FLUORENES; HUMANS; INFANT; MALARIA, FALCIPARUM; MALE; MIDDLE AGED; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84929505628     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(15)70024-1     Document Type: Article

References (32)

1. World malaria report 2013 WHO, (accessed March 19, 2014). http://www.who.int/malaria/publications/world_malaria_report_2013/en/.
2. White N Antimalarial drug resistance and combination chemotherapy. Philos Trans R Soc L B Biol Sci 1999, 354:739-749.
3. White NJ The role of anti-malarial drugs in eliminating malaria. Malar J 2008, 7(suppl 1):S8.
4. Jiao X, Liu GY, Shan CO, et al. Phase II trial in China of a new, rapidly-acting and effective oral antimalarial, CGP 56697, for the treatment of Plasmodium falciparum malaria. Southeast Asian J Trop Med Public Health 1997, 28:476-481.
5. Hatz C, Abdulla S, Mull R, et al. Efficacy and safety of CGP 56697 (artemether and benflumetol) compared with chloroquine to treat acute falciparum malaria in Tanzanian children aged 1-5 years. Trop Med Int Health 1998, 3:498-504.
6. Kshirsagar NA, Gogtay NJ, Moorthy NS, et al. A randomized, double-blind, parallel-group, comparative safety, and efficacy trial of oral co-artemether versus oral chloroquine in the treatment of acute uncomplicated Plasmodium falciparum malaria in adults in India. Am J Trop Med Hyg 2000, 62:402-408.
7. Ezzet F, van Vugt M, Nosten F, Looareesuwan S, White NJ Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. Antimicrob Agents Chemother 2000, 44:697-704.
8. Vugt MV, Wilairatana P, Gemperli B, et al. Efficacy of six doses of artemether-lumefantrine (benflumetol) in multidrug-resistant Plasmodium falciparum malaria. Am J Trop Med Hyg 1999, 60:936-942.
9. Falade C, Makanga M, Premji Z, Ortmann CE, Stockmeyer M, de Palacios PI Efficacy and safety of artemether-lumefantrine (Coartem) tablets (six-dose regimen) in African infants and children with acute, uncomplicated falciparum malaria. Trans R Soc Trop Med Hyg 2005, 99:459-467.
10. Hutagalung R, Paiphun L, Ashley EA, et al. A randomized trial of artemether-lumefantrine versus mefloquine-artesunate for the treatment of uncomplicated multi-drug resistant Plasmodium falciparum on the western border of Thailand. Malar J 2005, 4:46.
11. Abdulla S, Sagara I, Borrmann S, et al. Efficacy and safety of artemether-lumefantrine dispersible tablets compared with crushed commercial tablets in African infants and children with uncomplicated malaria: a randomised, single-blind, multicentre trial. Lancet 2008, 372:1819-1827.
12. Coartem Dispersible 200 million treatments dispatched MMV, (accessed Dec 18, 2013). http://www.mmv.org/achievements-challenges/achievements/coartem-d.
13. Song J, Socheat D, Tan B, et al. Randomized trials of artemisinin-piperaquine, dihydroartemisinin-piperaquine phosphate and artemether-lumefantrine for the treatment of multi-drug resistant falciparum malaria in Cambodia-Thailand border area. Malar J 2011, 10:231.
14. Tarning J, Zongo I, Some FA, et al. Population pharmacokinetics and pharmacodynamics of piperaquine in children with uncomplicated falciparum malaria. Clin Pharmacol Ther 2012, 91:497-505.
15. The effect of dosing regimens on the antimalarial efficacy of dihydroartemisinin-piperaquine: a pooled analysis of individual patient data. PLoS Med 2013, 10:e1001564. WorldWide Antimalarial Resistance Network (WWARN) DP Study Group.
16. Clinical module: data management and statistical analysis plan. Version 1.2. Oxford WWARN, (accessed March 19, 2014). http://www.wwarn.org/sites/default/files/ClinicalDMSAP.pdf.
17. Gething PW, Patil AP, Smith DL, et al. A new world malaria map: Plasmodium falciparum endemicity in 2010. Malar J 2011, 10:378.
18. WHO child growth standards: length/height-for-age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age: methods and development 2006, WHO, World Health Organization, Geneva.
19. Statistical analysis plan AL dose impact study group. Version 1.9. Oxford WWARN, (accessed March 19, 2014). http://www.wwarn.org/sites/default/files/DHA-PQPDoseImpactStudyGroupSAP.pdf.
20. Glidden DV, Vittinghoff E Modelling clustered survival data from multicentre clinical trials. Stat Med 2004, 23:369-388.
21. Schoenfeld D Partial residuals for the proportional hazards regression model. Biometrika 1982, 69:239-241.
22. Levin ML The occurrence of lung cancer in man. Acta Unio Int Contra Cancrum 1953, 9:531-541.
23. Dondorp AM, Nosten F, Yi P, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 2009, 361:455-467.
24. Venkatesan M, Gadalla NB, Stepniewska K, et al. Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine. Am J Trop Med Hyg 2014, 91:833-843.
25. Price R, Luxemburger C, van Vugt M, et al. Artesunate and mefloquine in the treatment of uncomplicated multidrug-resistant hyperparasitaemic falciparum malaria. Trans R Soc Trop Med Hyg 1998, 92:207-211.
26. Nacher M, Carrara VI, Ashley E, et al. Seasonal variation in hyperparasitaemia and gametocyte carriage in patients with Plasmodium falciparum malaria on the Thai-Burmese border. Trans R Soc Trop Med Hyg 2004, 98:322-328.
27. White NJ The assessment of antimalarial drug efficacy. Trends Parasitol 2002, 18:458-464.
28. Verret WJ, Arinaitwe E, Wanzira H, et al. Effect of nutritional status on response to treatment with artemisinin-based combination therapy in young Ugandan children with malaria. Antimicrob Agents Chemother 2011, 55:2629-2635.
29. White NJ, van Vugt M, Ezzet F Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether-lumefantrine. Clin Pharmacokinet 1999, 37:105-125.
30. Salman S, Page-Sharp M, Griffin S, et al. Population pharmacokinetics of artemether, lumefantrine, and their respective metabolites in Papua New Guinean children with uncomplicated malaria. Antimicrob Agents Chemother 2011, 55:5306-5313.
31. Oshikoya KA, Senbanjo IO Pathophysiological changes that affect drug disposition in protein-energy malnourished children. Nutr Metab (Lond) 2009, 6:50.
32. Ashley EA, Stepniewska K, Lindegardh N, et al. Pharmacokinetic study of artemether-lumefantrine given once daily for the treatment of uncomplicated multidrug-resistant falciparum malaria. Trop Med Int Heal 2007, 12:201-208.